首页 Sunesis制药(usSNSS)-基本信息

Sunesis制药(usSNSS)-基本信息

日报更新时间:

周报更新时间:01-23 11:54

行情信息

今开价:

最高价:

成交量:

昨收价:

最低价:

最新价:

行情图标
概要信息

中文名称:Sunesis制药


英文名称:Sunesis Pharmaceuticals


行业:医疗


简介:Sunesis Pharmaceuticals, Inc.于1998年2月10日在特拉华州注册成立


电话:1-650-2663500


最新量化综合结论
百科信息
  • 相关网站
  • 百科
  • 员工交易记录
  • 持股信息
  • 领导人信息

Sunesis是一家生物制药公司,专注于治疗血液和实体肿瘤癌症的新肿瘤治疗药物的开发和未来商业化。Sunesis建立了一个经验丰富的癌症药物开发组织,致力于改善癌症患者的生活。Sunesis制药公司致力于推进其新型激酶抑制剂管道,重点是建立口服非共价BTK抑制剂vecabrutinib(SNS-062)在治疗依鲁替尼耐药慢性淋巴细胞白血病方面有效的概念证据。 Sunesis公司主要项目是vecabrutinib,一种非共价结合的Bruton酪氨酸激酶抑制剂(BTK),正在进行B细胞恶性肿瘤的 Ib/II 期临床试验。 公司还致力于开发TAK-580,这是一种泛Raf抑制剂项目,与各种抗癌药物联合用于治疗成人患者的晚期实体瘤。 SNS-510,用于治疗实体瘤和血液系统恶性肿瘤的临床前药理学和毒理学研究。 vosaroxin,一种抗癌喹诺酮衍生物,用于治疗急性髓性白血病(AML)。 此外,Sunesis制药公司正在开发vosaroxin,结合地西他滨(decitabine)治疗急性AML或骨髓增生异常综合征(MDS),目前处于 II 期临床试验阶段;结合阿扎胞苷(azacitidine)治疗MDS,处于 I/II 期临床试验阶段;结合输注阿糖胞苷(cytarabine)治疗AML,目前处于 II 期临床试验阶段;对先前接受治疗的中度-2或高危MDS成人患者进行 I/II 期临床试验;结合阿糖胞苷进行的 I/II 期试验作为巩固治疗进行了测试。Sunesis Pharmaceuticals Inc.与Biogen Idec MA, Inc.签署有合作协议,合作发现,开发和商业化小分子BTK抑制剂;与Takeda Pharmaceutical Company Limited签署有授权协议,开发和商业化磷酸肌醇依赖性激酶-1的抑制剂。

交易日期 交易人 职位 类型 交易份额 价格
2019-02-27 Quinn (William P) Chief Financial Officer Buy 63697 --
2018-12-09 Quinn (William P) Chief Financial Officer Buy 40000 0.47
2017-11-05 MPM Oncology Impact Management G Beneficial Owner of More than 10% Class Buy 16200 2.77
2017-11-02 MPM Oncology Impact Management G Beneficial Owner of More than 10% Class Buy 40000 2.89
2017-11-01 MPM Oncology Impact Management G Beneficial Owner of More than 10% Class Buy 25300 2.59
2017-10-26 Misfeldt (Dayton) Director Buy 392520 2.00
2017-10-26 Misfeldt (Dayton) Director Buy 7480 2.00

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
BlackRock Inc 219135 0.30% 46852 27.19% 2019-03-31
Wells Fargo & Co 939958 1.30% 880711 1486.51% 2019-03-31
PURA VIDA INVESTMENTS, LLC 1157319 1.60% 1157319 -- 2019-03-31
Palo Alto Investors, LLC 1162473 1.60% -- -- 2019-03-31
NEA Management Company, LLC 1298274 1.79% -- -- 2019-03-31
Vanguard Investments Australia Ltd 1366486 1.88% -- -- 2019-07-31
Balyasny Asset Management LLC 2200000 3.03% -- -- 2019-03-31
Bvf Inc 2287860 3.15% -- -- 2019-03-31
Eventide Asset Management, LLC 5965455 8.23% 3700000 163.32% 2019-03-31
Fosun International Ltd 725000 1.00% 725000 -- 2019-03-31
Hauck & Aufh 725000 1.00% -- -- 2019-07-31
Vanguard Group Inc 696226 0.96% 279969 67.26% 2019-03-31
Caxton Corp 277245 0.38% 277245 -- 2019-03-31
Arnhold & S. Bleichroeder Advisers, LLC 294480 0.41% -- -- 2019-03-31
Geode Capital Management, LLC 314975 0.43% -10789 -3.31% 2019-03-31
Citadel Advisors Llc 319896 0.44% 293870 1129.14% 2019-03-31
Rhenman & Partners Asset Management AB 377244 0.52% -- -- 2019-07-31
Rhenman Partners Asset Management AB 377244 0.52% -- -- 2019-03-31
Fidelity Management & Research Company 435085 0.60% -- -- 2019-07-31
Baker Bros Advisors LP 556665 0.77% -- -- 2019-03-31
Sabby Management LLC 400140 0.55% 121956 43.84% 2018-12-31
Telemetry Investments, L.L.C. 197564 0.27% 173858 733.39% 2019-03-31
Northern Trust Corp 107116 0.15% 36296 51.25% 2019-03-31
BlackRock Fund Advisors 134857 0.19% -- -- 2019-05-31
Great Point Partners LLC 317962 0.44% -682038 -68.20% 2018-12-31
Vivo Capital, LLC 195474 0.29% -- -- 2018-12-31
Jacobs Levy Equity Management, Inc. 133607 0.20% 66599 99.39% 2018-12-31
Northern Trust Investments Inc 93159 0.14% 23767 34.25% 2019-04-30
Reichmuth & Co Integrale Vermogensverwaltung AG 96000 0.14% -- -- 2019-04-30
VATERA HOLDINGS LLC 182395 0.49% -- -- 2018-09-30
Dafna Capital Management LLC 373702 1.00% -- -- 2018-09-30
Boxer Capital LLC 2125000 5.68% -- -- 2018-09-30
Wells Fargo Advisors, LLC 96138 0.26% -40485 -29.63% 2018-09-30
Adage Capital Partners Gp LLC 100000 0.27% -- -- 2018-09-30
Goldman, Sachs & Co. 162198 0.43% 162198 -- 2018-03-31
Goldman Sachs Group Inc 162198 0.43% 162198 -- 2018-03-31
RA Capital Management, LLC 2471456 6.60% -625384 -20.19% 2018-03-31
Driehaus Capital Management LLC 243730 0.65% -7572 -3.01% 2018-10-31
UBS Oncology Impact Fund L.P. 3331500 9.72% 3331500 -- 2017-12-31
Aisling CapitalPartners IV LLC 2600000 7.58% 1306426 100.99% 2017-12-31
Bay City Capital LLC 1628968 4.76% 1628968 -- 2017-10-27
Balyasny Asset Management L.P. 2200000 6.42% 2200000 -- 2017-12-31
Two Sigma Investments LLC 105013 0.30% 85583 440.47% 2018-06-30
Millennium Management LLC 106599 0.31% 91248 594.41% 2018-03-31
Susquehanna Financial Group, LLLP 135049 0.39% 135049 -- 2018-03-31
Northern Trust Investments N A 67170 0.20% 36320 117.73% 2017-12-31
Medical Strategy GmbH 60000 0.17% -- -- 2018-02-28
Balyasny Asset Management LP 2000000 9.32% 2000000 -- 2017-06-23
Sphera Funds Management Ltd. 111762 0.47% -81450 -42.16% 2017-09-30
Renaissance Technologies Corp 74481 0.31% -16200 -17.86% 2017-09-30
BlackRock Institutional Trust Company NA 65580 0.27% -- -- 2017-09-30
Cormorant Asset Management, LLC 1000000 6.90% 1000000 -- 2016-10-19
KCG AMERICAS LLC 76910 0.33% 76910 -- 2017-06-30
Opaleye Management Inc 380000 1.62% -170000 -30.91% 2017-06-30
Frontier Wealth Management, LLC 133300 0.92% 54458 69.07% 2016-09-30
Federated Investment Management Company 110000 0.76% 43336 65.01% 2016-09-30
Neuberger Berman Investment Advisers LLC 120555 0.58% -4445 -3.56% 2016-12-31
Franklin Street Advisors Inc. 33332 0.16% -- -- 2016-12-31
Guggenheim Capital LLC 22301 0.15% 18133 435.05% 2016-09-30
California Public Employees Retrmnt Sys 19416 0.13% 19416 -- 2016-09-30
Dayton Misfeldt 4624836 3.00% 11145855 0.10% 1999-11-30
Growth Equity Opportunities Fund, LLC 4659333 3.00% 11228993 0.10% 1999-11-30
FMR LLC 5083834 3.00% 12252040 0.10% 1999-11-30
T. Rowe Price Associates, Inc. 5670000 3.00% 13664700 0.10% 1999-11-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
NT Extended Equity Market Idx Fund - NL 72209 0.10% 50036 225.66% 2019-06-30
Vanguard Total Stock Market Index Fund 1366486 1.88% -- -- 2019-06-30
Vanguard Extended Market Index Fund 804130 1.11% -- -- 2019-06-30
MEDICAL BioHealth 725000 1.00% -- -- 2019-04-30
Rhenman Healthcare Eq L/S 377244 0.52% -- -- 2019-04-30
iShares Micro-Cap ETF 158259 0.22% -- -- 2019-07-30
Vanguard Instl Total Stock Market Idx Fd 87715 0.12% -- -- 2019-06-30
iShares Core S&P Total US Stock Mkt ETF 7015 0.01% -- -- 2019-07-30
Fidelity 57085 0.08% -- -- 2019-06-30
NT Ext Equity Mkt Fd - DC - NL 51667 0.07% 36956 251.21% 2019-06-30
NT Ext Equity Market Index Fund - L 51122 0.07% -- -- 2019-06-30
BlackRock Extended Equity Market 14731 0.02% -20 -0.14% 2019-06-30
State Street U.S. Extended Market Index 11985 0.02% -- -- 2019-07-31
NT US Market Cap Index Fund - Lending 11756 0.02% 6603 128.14% 2019-06-30
Vanguard US Equity Index Fund 11480 0.02% -- -- 2019-06-30
1290 VT Micro Cap Portfolio 10140 0.01% -- -- 2019-05-31
Vanguard Balanced Index Fund 7041 0.01% -- -- 2019-06-30
Eventide Healthcare & Life Sciences Fund 5965455 8.23% 3700000 163.32% 2019-03-31
NT Ext Equity Mkt Idx Fd - DC - NL 51667 0.07% 36956 251.21% 2019-06-30
RIM Global Bioscience 96000 0.13% -- -- 2019-05-31
BNYM Mellon NSL Mkt Completion Fd Instl 7547 0.01% 6066 409.59% 2019-03-31
PHARMA/wHEALTH 12000 0.02% -- -- 2018-07-31
BNYM Mellon NSL Market Completion Fund 7547 0.01% 6066 409.59% 2019-03-31
The Vanguard Total Stock Market Index 6416 0.01% -- -- 2019-03-31
BNYM Mellon SL Mkt Completion Fd 7547 0.01% 6066 409.59% 2019-03-31
JHVIT Total Stock Market Index Trust Fd 1269 -- -- -- 2019-01-31
USAA Extended Market Index Fund 2343 -- -- -- 2019-02-28
Spartan Total Market Index Pool 3162 -- -- -- 2019-01-31
Vanguard U.S. All-Cap Equity Idx Pooled 26 -- -- -- 2019-01-31
BNY Mellon Market Completion Fund 1481 -- -838 -36.14% 2018-12-31
Blackstone Alternative Multi-Strategy Fd 67 -- 67 -- 2018-06-30
JHVIT Total Stock Market Index Tr 1269 -- -- -- 2018-12-31
Invesco Wilshire Micro-Cap ETF 6908 0.02% -- -- 2019-01-31
Next Edge Bio-Tech Plus Fd 85000 0.23% 85000 -- 2018-09-30
RIM Global CC Bioscience 8000 0.02% -- -- 2018-07-31
SG Actions US Techno 22300 0.06% -- -- 2018-09-30
FCP MEDICAL BioHealth-Trends 60000 0.16% -- -- 2018-06-30
VAM US Micro Cap Growth Fund 9509 0.03% -4732 -33.23% 2017-07-31
HERCULIS Partners Aries 13333 0.04% -- -- 2018-01-31
HeptagonDriehaus US Micro Cap Equity Fd 17742 0.05% 823 4.86% 2017-07-31
Destinations Small-Mid Cap Equity Fund 40518 0.11% -- -- 2017-07-31
FCP MEDICAL BioHealth 60000 0.16% -- -- 2018-06-30
Driehaus Event Driven Fund 112500 0.30% -- -- 2017-07-31
Driehaus Micro Cap Growth Fund 121721 0.33% -2840 -2.28% 2017-07-31
Vanguard Balanced Index Inv 22341 0.06% -- -- 2018-07-31
Fidelity Spartan 29991 0.09% -- -- 2018-07-31
Vanguard Instl Ttl Stk Mkt Idx InstlPls 45662 0.13% -- -- 2018-07-31
iShares Micro-Cap 88034 0.22% -- -- 2018-09-12
Vanguard Extended Market Idx Inv 363659 1.04% -- -- 2018-07-31
Vanguard Total Stock Mkt Idx 672732 1.93% -- -- 2018-07-31
Eventide Healthcare & Life Sciences A 2265455 6.50% -- -- 2018-06-30
BlackRock Extended Equity Market K 14631 0.04% 398 2.80% 2018-06-30
BNY Mellon EB DL Mkt Completion 7207 0.02% -- -- 2018-06-30
AXA/Lord Abbett Micro Cap K 6152 0.02% -- -- 2018-07-31
SSgA U.S. Total Market Index Fd Class I 526 -- -34 -6.07% 2017-12-31
JHVIT Total Stock Market Index I 1269 -- -- -- 2018-07-31
USAA Extended Market Index 2343 0.01% -- -- 2018-07-31
TFS Market Neutral 1350 0.01% -39067 -96.66% 2017-07-31
BNY Mellon Market Completion Fund UC1 2320 0.01% 819 54.56% 2018-03-31
iShares Core S&P Total US Stock Mkt 5352 0.01% -- -- 2018-09-12
Wilshire Micro-Cap ETF 7043 0.02% -- -- 2018-09-14
Master Extended Market Index Series 2343 0.01% -- -- 2018-01-31
QMA Wilshire 5000 Indexing CF 500 -- -- -- 2017-12-31
Driehaus Micro Cap Growth 178157 0.85% -15492 -8.00% 2016-12-31
Neuberger Berman Small Cap Growth Inv 120555 0.58% -4445 -3.56% 2016-12-31
Driehaus Event Driven 112500 0.54% -- -- 2016-12-31
Federated Absolute Return A 110000 0.53% -- -- 2016-12-31
Fidelity Advisor® Biotechnology Fund 830240 1.10% -- -- 2015-09-30
Pyramis Small Cap Core Tr 641990 1.10% 16800 2.70% 2014-09-30
Federated Absolute Return Fund 400000 0.50% -- -- 2015-09-30
Fidelity Spartan® Extended Mkt Indx Fd 279837 0.40% 90051 47.50% 2015-09-30
VAM Funds (Lux) ¨C US Micro Cap Growth 197061 0.30% -4834 -2.40% 2015-09-30
TD Health Sciences Fund 133600 0.20% -- -- 2015-06-30
Mellon Capital EB DL Mkt Completion Fund 54855 0.10% -- -- 2015-09-30
The Vanguard - Total Stk Mkt Idx Trust. CF 49600 0.10% -33300 -40.20% 2015-10-31
Fidelity® Select Biotechnology Portfolio 4253594 5.60% -- -- 2015-09-30

Steven B. Ketchum Currently, Steven B. Ketchum holds the position of Chief Scientific Officer & Senior Vice President at Amarin Corp. Plc. Dr. Ketchum is also on the board of Sunesis Pharmaceuticals, Inc. In the past he occupied the position of Senior VP-Operations & Regulatory Affairs at IntraBiotics Pharmaceuticals, Inc., Senior VP-Medical Affairs, Research & Development at Reliant Pharmaceuticals LLC and Senior Director-Regulatory Affairs at ALZA Corp. Dr. Ketchum received an undergraduate degree from Stanford University and a doctorate from University College London.
James W. Young Presently, James W. Young holds the position of Chairman at Chrono Therapeutics, Inc., Non-Executive Chairman of Sunesis Pharmaceuticals, Inc. and Venture Partner at 5AM Venture Management LLC. Dr. Young is also on the board of Impel NeuroPharma, Inc. and Portal Instruments, Inc. In his past career Dr. Young was Principal at Zoecon Corp., Chairman at Pearl Therapeutics, Inc., Senior Vice President-Research & Development at ALZA Corp., President-Pharmaceuticals Division at Affymax NV and Senior Vice President-Business Development of Sunovion Pharmaceuticals, Inc. James W. Young received a doctorate from Cornell University and an undergraduate degree from Fordham University.
David C. Stump David C. Stump is on the board of Sunesis Pharmaceuticals, Inc. and 4 other companies. In the past Dr. Stump held the position of Executive Vice President-Research & Development at Human Genome Sciences, Inc., Vice President-Clinical Research at Genentech, Inc. and Associate Professor at the University of Vermont. He received an undergraduate degree from Earlham College and a doctorate from Indiana University.
Henry Ward Wolff Henry Ward Wolff is on the board of Sunesis Pharmaceuticals, Inc., Portola Pharmaceuticals, Inc. and Calithera Biosciences, Inc. In the past he was Chief Financial Officer & Executive Vice President at Sangamo Therapeutics, Inc., Chief Financial Officer & Senior Vice President for DoubleTwist, Inc., Chief Financial Officer & Senior VP-Finance at Nuvelo, Inc., Chief Financial Officer & Senior VP-Finance at Abgenix, Inc., Chief Financial Officer at QuantumShift, Inc., Chief Financial Officer of Premenos Technology Corp. and Senior Audit Manager at Pricewaterhouse LLP. Mr. Wolff received an undergraduate degree from the University of California, Berkeley and an MBA from Harvard Business School.
Daniel N. Swisher Mr. Daniel N. Swisher is Chairman at Cerus Corp. He is on the Board of Directors at Corcept Therapeutics, Inc., The Okizu Foundation and Sunesis Pharmaceuticals, Inc. Mr. Swisher was previously employed as Senior Vice President-Sales & Marketing by ALZA Corp. He received his undergraduate degree from Yale University and an MBA from Stanford Graduate School of Business.
Homer L. Pearce Presently, Homer L. Pearce is Industry Expert at Pearl Street Venture Funds. He is also on the board of BioNumerik Pharmaceuticals, Inc., Sunesis Pharmaceuticals, Inc. and Apexian Pharmaceuticals, Inc. and Member of American Association for Cancer Research and Member of American Chemical Society. Dr. Pearce previously was VP-Cancer Research & Clinical Investigation at Eli Lilly & Co., Director & Scientific Advisor at Kylin Therapeutics, Inc. and Member of American Association for the Advancement of Science. He received a doctorate from Harvard University and an undergraduate degree from Texas A&M University.
Dayton Misfeldt Presently, Dayton Misfeldt holds the position of Chief Executive Officer & Director at Sunesis Pharmaceuticals, Inc. and Managing Director at Bay City Capital LLC. Mr. Misfeldt is also on the board of TRIA Beauty, Inc., Aciex Therapeutics, Inc. and Presidio Pharmaceuticals, Inc. In his past career Mr. Misfeldt occupied the position of Project Manager at Lifescience Economics and Vice President at ROTH Capital Partners LLC. He received an undergraduate degree from the University of California San Diego.
Judith A. Fox Presently, Judith A. Fox holds the position of Chief Scientific Officer & Executive VP at Sunesis Pharmaceuticals, Inc. She previously was Senior Vice President-Research & Development at Amphivena Therapeutics, Inc., Vice President-Product & Preclinical Development at Sunesis Pharmaceuticals, Inc. and Senior Director-Translational Sciences Department at Chiron Corp. Judith A. Fox received a doctorate from Massachusetts Institute of Technology and an undergraduate degree from Bryn Mawr College.
Dayton Misfeldt Presently, Dayton Misfeldt holds the position of Chief Executive Officer & Director at Sunesis Pharmaceuticals, Inc. and Managing Director at Bay City Capital LLC. Mr. Misfeldt is also on the board of TRIA Beauty, Inc., Aciex Therapeutics, Inc. and Presidio Pharmaceuticals, Inc. In his past career Mr. Misfeldt occupied the position of Project Manager at Lifescience Economics and Vice President at ROTH Capital Partners LLC. He received an undergraduate degree from the University of California San Diego.
Willie P. Quinn Founder of Bullet Biotechnology, Inc., Willie P. Quinn presently is CFO, Senior VP-Finance & Corporate Development at Sunesis Pharmaceuticals, Inc. He is also on the board of Neurogastrx, Inc., Solar Roof Dynamics LLC, Midnight Pharmaceuticals, Inc. and A Foundation Building Strength For Nemaline Myopathy. In the past Mr. Quinn occupied the position of President, Chief Executive Officer & Director at Bullet Biotechnology, Inc., Chief Financial & Operational Officer at Novation Biosciences, Inc., Associate Partner at MFVC, Inc. and Executive Director-Corporate Development at Jazz Pharmaceuticals, Inc. Willie P. Quinn received an MBA from Stanford Graduate School of Business and an undergraduate degree and a graduate degree from Stanford University.
Geoffrey M. Parker Mr. Geoffrey M. Parker is on the Board of Directors at Perrigo Co. Plc, Genomic Health, Inc., Sunesis Pharmaceuticals, Inc. and ChemoCentryx, Inc. Mr. Parker was previously employed as Chief Financial Officer & Senior Vice President by Anacor, Inc., Chief Financial Officer & Executive Vice President by Anacor Pharmaceuticals, Inc., Chief Business Officer by InteKrin Therapeutics, Inc., MD & Partner-Investment Banking Division by The Goldman Sachs Group, Inc., and Vice President by Feibusch & Co., Inc. He also served on the board at Genoptix, Inc. He received his undergraduate degree from Dartmouth College and an MBA from Stanford Graduate School of Business.
Steve Carchedi Presently, Steve Carchedi is President, Chief Executive Officer & Director at Apexian Pharmaceuticals, Inc. Mr. Carchedi is also on the board of BioNumerik Pharmaceuticals, Inc. and Sunesis Pharmaceuticals, Inc. and Member-Advisory Board at CMO Council. He previously held the position of Chief Executive Officer & Director at Cornerstone Pharmaceuticals, Inc., Global Marketing Leader at Johnson & Johnson and Principal at McNeil Consumer & Specialty Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson), Principal at Eli Lilly & Co., SVP-Oncology, Urology & Endocrinology at Enzon Pharmaceuticals, Inc., Principal at Bristol-Myers Squibb Co., Senior Vice President for Mallinckrodt Plc, Senior VP & President-Commercial Operations at Mallinckrodt Pharmaceuticals, Senior Vice President-Specialty Business at Endo Pharmaceuticals, Inc., Principal at Covidien Ltd., Chief Marketing Officer at GE Healthcare, Inc. and Member of Ontario Institute for Cancer Research. He received an undergraduate degree from West Chester University of Pennsylvania and an MBA from Drexel University.
Gene C. Jamieson Gene C. Jamieson is Vice President-Technical Operations at Sunesis Pharmaceuticals, Inc. In the past Mr. Jamieson was Vice President-Pharmaceutical Sciences at NeurogesX, Inc., Principle Partner at Ally CMC and Executive Director-Product Development at Jazz Pharmaceuticals, Inc. Mr. Jamieson received an undergraduate degree from Northern Illinois University.
Parvinder S. Hyare Parvinder S. Hyare is Senior Vice President-Commercial at Sunesis Pharmaceuticals, Inc. In his past career Mr. Hyare held the position of Executive Director-Managed Markets & Reimbursement at AMAG Pharmaceuticals, Inc. and Director-Region Business at Ortho Biotech Products LP. He received an undergraduate degree from California State University-Stanislaus.
Jennifer A. Smith Jennifer A. Smith is Vice President-Biometrics at Sunesis Pharmaceuticals, Inc. In the past Dr. Smith occupied the position of Senior Director-Biometrics at Geron Corp., Senior Director-Biometrics at BiPar Sciences, Inc. and Biostatistics Director at Pharmacyclics LLC. Dr. Smith received a doctorate and a graduate degree from Stanford University and an undergraduate degree from the University of Toronto.
Linda Neuman Dr. Linda Neuman is a Chief Medical Officer at Adverum Biotechnologies, Inc. and a Vice President-Clinical Development at Sunesis Pharmaceuticals, Inc. She received her undergraduate degree from Southern Illinois University, an MBA from Indiana Wesleyan University and a doctorate degree from Southern Illinois University.
Deepali Suri Deepali Suri is Vice President-Clinical Operations at Sunesis Pharmaceuticals, Inc. In the past Ms. Suri occupied the position of Executive Director-Clinical Operations at Pharmacyclics LLC. She received an undergraduate degree and a graduate degree from the University of Delhi.
Sean Gharpurey Sean Gharpurey is Executive Director-Project Management at Sunesis Pharmaceuticals, Inc. Mr. Gharpurey received an MBA from the University of North Carolina at Chapel Hill, a graduate degree from the University of Missouri and an undergraduate degree from Indian Institute of Technology Bombay.
Stephen Nava Currently, Stephen Nava is Vice President-Compliance & Regulatory Affairs at Sunesis Pharmaceuticals, Inc. He is also Owner at Regulator Affairs Quality Assurance Consulting Services, Inc. Mr. Nava previously held the position of Director-Regulatory Affairs at Acumen Sciences LLC and Director-Regulatory Affairs & Quality Assurance at BiPar Sciences, Inc. Stephen Nava received an undergraduate degree from Texas A&M University-Kingsville.

量化对比

全部评论 0

  • 暂无评论

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐